Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida

Cohort study (n=515) found antibody responses to the Moderna Covid-19 vaccine (mRNA-1273) were variable and differed by cancer diagnosis and treatment received; the authors suggest those with haematological cancer and those receiving immunosuppressants may need additional doses

SPS commentary:

The authors reported that seropositivity after the second vaccine dose was lower among those with haematological cancer (84.7% vs 98.1% in those with solid tumours), lowest among patients with lymphoid cancer (70.0%).

Those who received vaccination within 6 months of anti-CD20 monoclonal antibody treatment had a significantly lower seroconversion compared with those treated 6 to 24 months earlier (6.3% v 53.3%) or those who never received anti-CD20 treatment (94.2%).

JAMA Oncology